Polymerase Chain Reaction Market – Insights

Key players in the polymerase chain reaction market are engaged in launching advanced and novel PCR instruments and consumables, which will allows rapid and easy nucleic acid amplification. For instance, in October 2017, Diatech Pharmacogenetics srl launched easyPGX: a ready to use in-vitro diagnostic real-time PCR product line and Helix: a polymerase chain reaction kit for the extraction of circulating free DNA from plasma. In September 2015, Bio-Rad Laboratories launched droplet digital PCR (ddPCR) Supermix for Residual DNA Quantification. The new supermix designed to use with Bio-Rad’s Droplet Digital PCR Systems offers highly precise and sensitive method for DNA measurement. In November 2014, Chai Biotechnologies Inc. introduced Open qPCR: Real-Time PCR Thermocycler. The new instrument is designed to use for genetic genotyping, pathogen detection, and relative DNA quantification. Moreover, in April 2014, Bio-Rad Laboratories launched Precision Blue Real-Time PCR Dye. The new Precision Blue dye is compatible with Bio-Rad’s universal qPCR supermixes, and can be used with all Bio-Rad’s CFx real time PCR systems.

Get The Holistic SAMPLE Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1546

Furthermore, key players are involved in several collaborations to expand their geographical horizon and increase patient reach. For instance, in March 2018, Akonni Biosystems Inc. and a Chinese in-vitro diagnostics company: Righton signed a commercial agreement, which enables Righton to sell Akonni's TruDiagnosis and TruTip Nucleic Acid Purification Kits in China. TruDiagnosis is based on proprietary on-slide PCR and gel-drop microarray technology. In January 2018, Thermo Fisher Scientific and Illumina, Inc. signed a commercial agreement. Under the agreement, Thermo Fisher will provide Ion AmpliSeq technology to Illumina for research purpose. Moreover, in December 2017, Genome Diagnostics (GenDx) signed a global reseller agreement with Thermo Fisher Scientific, assigning GenDx as a non-exclusive reseller of Thermo Fisher’s QuantStudio real-time PCR instrument. Under the agreement, GenDx will market the QuantStudio real-time PCR in the Netherlands and other European countries. Thus, significant organic and inorganic growth strategies by various key players is driving growth of the polymerase chain reaction market.

However, advances in research are leading to generation of various alternative nucleic acid amplification methods, which may hinder growth of the polymerase chain reaction market over the forecasted period. Such alternative methods of nucleic acid amplification includes loop medicated isothermal amplification, nucleic acid sequence based amplification, strand displacement amplification, and multiple displacement amplification. These methods offers better applicability and sensitivity in nucleic acid amplification, where PCR shows limitations such as contamination, sensitivity to certain classes of contaminants and inhibitors, and requirement of thermal cycling. Key players in the polymerase chain reaction are engaged in offering PCR-free nucleic acid detection methods. For instance, in March 2018, Quanterix Corporation and DestiNA Genomics collaborated to develop PCR-free microRNA detection method with high-specificity and ultra-sensitivity, thereby enhancing RNA biomarker detection.

Download The PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1546

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website:https://www.coherentwire.com

This release was published on openPR.